{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:31:47Z","timestamp":1740177107090,"version":"3.37.3"},"reference-count":0,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Gastroenterology"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>OBJECTIVE: To assess<jats:italic>Helicobacter pylori<\/jats:italic>eradication after one week dual ranitidine bismuth citrate-clarithromycin (RBC-C) or triple omeprazole, clarithromycin and amoxicillin (OCA) therapy.<\/jats:p><jats:p>METHODS: In this multicentre Canadian trial,<jats:italic>H pylori-<\/jats:italic>positive patients with functional dyspepsia or inactive peptic ulcer disease were randomized to open-label treatment with RBC-C (ranitidine bismuth citrate 400 mg plus clarithromycin 500 mg) or OCA (omezaprole 20 mg, clarithromycin 500 mg and amoxicillin 1000 mg), given twice a day for seven days. Treatment allocation was randomly assigned.<jats:italic>H pylori<\/jats:italic>infection was confirmed by positive<jats:sup>13<\/jats:sup>C-urea breath test (<jats:sup>13<\/jats:sup>C-UBT).<jats:italic>H pylori<\/jats:italic>status was reassessed by UBT at least four and 12 weeks after treatment (negative: \u03b4<jats:sup>13<\/jats:sup>CO<jats:sub>2<\/jats:sub>below 3.5 per mil). Intention-to-treat (ITT) eradication rates were determined for all patients with confirmed<jats:italic>H pylori<\/jats:italic>infection. Per protocol (PP) rate was determined for all patients treated with at least two evaluable follow-up visits.<\/jats:p><jats:p>RESULTS: Three hundred five patients were included in the ITT and 222 in the PP analysis. The ITT eradication rates were 66% for RBC-C and 78% for OCA. The PP success rates were 84% for RBC-C and 96% for OCA. The difference for both ITT 12% (95% CI 2 to 22) and PP 12% (95% CI 4 to 19) were statistically significant, P=0.030 and P=0.007, respectively. Treatment was generally well tolerated.<\/jats:p><jats:p>CONCLUSION: The eradication rate for the seven-day dual RBC-C regimen was lower than that for OCA.<\/jats:p>","DOI":"10.1155\/2003\/425293","type":"journal-article","created":{"date-parts":[[2016,3,20]],"date-time":"2016-03-20T17:01:23Z","timestamp":1458493283000},"page":"533-538","source":"Crossref","is-referenced-by-count":4,"title":["A Randomized Trial Comparing Seven-Day Ranitidine Bismuth Citrate and Clarithromycin Dual Therapy to Seven-Day Omeprazole, Clarithromycin and Amoxicillin Triple Therapy for the Eradication of<i>Helicobacter pylori<\/i>"],"prefix":"10.1155","volume":"17","author":[{"given":"Sander Veldhuyzen","family":"van Zanten","sequence":"first","affiliation":[{"name":"Dalhousie University, Department of Medicine, Division of Gastroenterology, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Chiba","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Barkun","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Fallone","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Farley","sequence":"additional","affiliation":[{"name":"Centre de Gastro-enterologie de Montreal, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Cockeram","sequence":"additional","affiliation":[{"name":"Saint John Regional Hospital, Saint John, New Brunswick, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystian","family":"Dallaire","sequence":"additional","affiliation":[{"name":"Hopital Saint Francois d\u0092Assise, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Simms","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Beecham (Canada) Inc, Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Nicholls","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Beecham (Canada) Inc, Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","container-title":["Canadian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2003\/425293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2003\/425293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T05:42:05Z","timestamp":1471930925000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/cjgh\/2003\/425293\/abs\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003]]}},"alternative-id":["425293"],"URL":"https:\/\/doi.org\/10.1155\/2003\/425293","relation":{},"ISSN":["0835-7900"],"issn-type":[{"type":"print","value":"0835-7900"}],"subject":[],"published":{"date-parts":[[2003]]}}}